

DETERMA Rx™

Confident treatment decisions in NSCLC

DetermaRx™ is a treatment stratification test to identify patients with Stage I-IIA non-squamous NSCLC who may benefit from adjuvant chemotherapy.¹

40,000+

patients are diagnosed with early-stage non-small cell lung cancer (NSCLC) each year.²

30-50%

of early-stage patients will not survive despite complete surgical resection.³

We need a

better way

to understand which patients may benefit from chemotherapy.

DetermaRx Identify your patients who may benefit from chemotherapy


Resected, NSCLC FFPE Sample

RNA Expression via qPCR

Proprietary Algorithm

Cancer-Related Target Genes (11)

BAG1	ERBB3	RND3
BRCA	FUT3	SH3BGR
CDC6	IL11	WNT3A
CDKAP1	LKC	

Reference Genes (3)

ESD
TBP
YAP1



High-Risk Patients

Intermediate-Risk Patients


Low-Risk Patients

See our Clinical Evidence


- 14-gene molecular stratification test that has been validated in two independent cohorts with close to 1400 patients.⁴
- Outperformed NCCN criteria in identifying patients at high-risk for mortality from stage IA, IB, and IIA non-squamous NSCLC.⁴
- Test-identified high-risk* patients who were treated with adjuvant platinum chemotherapy had **91.7% 5-year disease-free survival (DFS)** compared to 48.9% 5-year DFS for high-risk patients who did not receive chemotherapy.¹
- Results led to a change in treatment recommendation for 30% of patients in a study of physician practices.⁵

*Test identified intermediate- and high-risk patients were grouped together in this analysis and designated as molecular high-risk.

DETERMA RxTM
Where Tomorrow **LIVES**



UCSF TREATMENT STRATIFICATION COHORT



**Oncocyte is committed
to serving patients
and physicians**



When should you order DetermaRx?

- If a patient has been diagnosed with stage IA, IB, or IIA non-squamous non-small cell lung cancer (NSCLC) with a tumor size of less than 5 cm and with no nodal involvement.
- Has undergone surgical resection.
- Is being considered for chemotherapy in the next stage of their care.



We're here to help

Oncocyte Customer Service can answer any questions you have. Please contact us at:

1.844.662.6298 or customer.service@oncocyte.com

Visit our website to learn more:

<https://oncocyte.com/determarx-how-to-order>

REFERENCES 1. Woodard, et al. (2018) Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small-cell lung cancer. Clin Lung Cancer 19:58-64 2. SEER data 3. Detterbeck, et al. (2017) The eighth edition lung cancer stage classification. Chest 151:193-203 4. Kratz, et al. (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 379:823-32 5. Dormady, et al. (2015) The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer. Int J Clin Oncol 20:59-69

ONCOCYTE CORPORATIONTM 15 Cushing / Irvine, CA 92618 / www.oncocyte.com / info@oncocyte.com / 949.409.7600

ONCOCYTETM

©2020 Oncocyte Corporation. All rights reserved. Oncocyte and DetermaRx are trademarks of Oncocyte Corporation in the U.S. and other countries. All other trademarks are the property of their respective owners in the United States and other countries. For the DetermaRx intended uses, please refer to www.oncocyte.com

MKT 0518 0520